Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that doctors eagerly await the launch of Alza's iontophoretic fentanyl patch (IONSYS) in 2007. Although physicians interviewed voice enthusiasm about Alza's patch, it is unlikely that this agent will reach blockbuster status in the postoperative pain market. The report entitled Postoperative Pain finds that generic competition, formulary restrictions, short-treatment periods, and market saturation will be hurdles too high to overcome for any emerging therapy for postoperative pain over the next ten years. As a result, this market grows at a slow but steady rate.

"Payers are unlikely to accept drastically more expensive agents on the hospital formulary unless the agents represent a significant improvement over existing agents in safety or efficacy," said Michelle Grady, therapeutic area director at Decision Resources.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http;//www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Local Blues Davids Take on National Medicare Goliaths

View Now